DEFINITION of 'Abbreviated New Drug Application (ANDA)'

Abbreviated New Drug Application (ANDA) is a written request to the U.S. Food and Drug Administration (FDA) to manufacture and market a generic drug in the United States. Abbreviated New Drug Applications are “abbreviated” since they do not require the applicant to conduct clinical trials and require less information than a New Drug Application.

BREAKING DOWN 'Abbreviated New Drug Application (ANDA)'

A company that wants to market a generic drug needs to show the Food & Drug Administration (FDA) that the drug has been found to be bioequivalent - meaning it gets to the part of the body where the drug works at the same time and in the same amount as the brand-name drug - through testing the generic version against the brand-name version on a small group of test subjects. Statistical analysis of the test samples must show that there is no significant difference between the two. This process is considerably less rigorous than the clinical trials that new drugs must go through. An exception applies to biosimilars, the generic equivalents of biologic drugs. Biosimilars may require clinical trials because it is harder to achieve bioequivalence with these drugs.

An ANDA lists the new drug’s established name, trade name (if any), chemical name, dosage form(s) and strength(s), route of administration and proposed use. It asks for the name of the listed drug product that the proposed generic is equivalent to. It also asks if the drug is for the treatment of a rare disease, and whether the drug will be over-the-counter or prescription-only. The applicant may be required to attach supplemental data about drug chemistry, manufacturing and controls and other technical information.

If an ANDA is approved, the generic drug will be listed in the Orange Book, which lists all medicines the FDA has found to be safe, effective, and low cost alternative to the public. An ANDA contains the information the FDA needs to evaluate how safe and effective a proposed generic drug is compared with its brand-name equivalent. The FDA will not approve the generic unless it is equally safe and effective.

Generic drugmakers will typically file an ANDA when the patent protection period of a brand-name drug is about to expire. As a result, news of an ANDA filing can cause the share price of a brand-name drugmaker to drop and the share price of a generic drugmaker to climb, creating a new revenue opportunity for the latter. Investors should note that filing an ANDA does not guarantee approval by the FDA. Therefore, they should do their due diligence when an ANDA is filed by examining the submitted 10-K report of the drugmaker.

RELATED TERMS
  1. Abbreviated New Drug Submission ...

    An Abbreviated New Drug Submission (ANDS) is a written request ...
  2. Generic Brand

    A generic brand is a type of consumer product that lacks a widely ...
  3. Food And Drug Administration (FDA)

    The Food and Drug Administration is a government agency that ...
  4. Blockbuster Drug

    A blockbuster drug is an extremely popular drug that generates ...
  5. Healthcare Sector

    The healthcare sector consists of companies that provide medical ...
  6. Phase 3

    Phase 3 is the final phase of clinical trials for an experimental ...
Related Articles
  1. Investing

    Cost of Old Cancer Drugs Rises in EU Amid Outcry

    The prices of several off-patent cancer drugs have soared more than 100% in Europe.
  2. Investing

    Drug Approvals Fell to Six-Year Low in 2016

    New drug approvals dropped to modest levels in 2016 following highs in 2014 and 2015.
  3. Investing

    Market Vectors Launches First Generic Drugs ETF (GNRX)

    Generic drugs have been a growing market in recent years. Now there is an ETF targeted at this market.
  4. Investing

    Pharma Balks at German Price Control (BAYRY, RHHBY)

    Drug makers are worried about a proposed new German law that would tighten price controls on prescription drugs.
  5. Investing

    It's No Accident That Drugs Are Expensive

    Branded drugs are expensive in large part because it's expensive and risky to develop them
  6. Investing

    Using DCF In Biotech Valuation

    Valuing firms in this sector can seem like a black art, but there is a systematic way to pin a price on potential.
  7. Insights

    Drug Prices Gone Wild: Hospitals Feel Pain of Increases

    Hospitals and patients are suffering as prices soar for both branded and generic drugs
  8. Financial Advisor

    8 Hacks for Scoring Cheaper Prescription Drugs

    The rising cost of prescription drugs has caused many patients to scramble for funds. Here's what you can do to help clients lower pharmacy costs.
  9. Investing

    Where Does the US Get Its Supply of Drugs?

    Despite increasing demands for local production, the US imports only a small portion of its drugs.
  10. Insights

    Why Drug Prices Keep Rising & How to Fight Back

    Despite pushback from politicians and disgruntled consumers, the cost of drugs keeps going up. Is there any relief on the horizon?
RELATED FAQS
  1. Can your insurance company drug test you?

    Learn why insurance companies conduct drug tests and how a lifestyle free of drugs can save you big money on health and life ... Read Answer >>
  2. What is the average price-to-earnings ratio in the drugs sector?

    Learn what the average price-to-earnings ratio is for companies operating in the drugs sector and why this metric is important ... Read Answer >>
  3. Who are Gilead Sciences' (GILD) main competitors?

    Learn about the pharmaceutical company Gilead Sciences and its main competitors. Explore the company's role in creating HIV-preventing ... Read Answer >>
  4. How does specialization help companies achieve economies of scale?

    Learn the definition of economies of scale, why it is important and how specialization during production can lead to economies ... Read Answer >>
Trading Center